As CAR T cells are increasingly explored in multiple disease indications (55), a second generation anti–PD-1 CAR approach could be considered in oncology to treat selective PD-1–expressing tumors such as angioimmunoblastic T cell lymphoma (56–59) and nodal peripheral T cell lymphomas with TFH markers (60). The gene discussed is PDCD1; the disease is angioimmunoblastic T-cell lymphoma.